Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
| Autor: | Tanin Intragumtornchai, Kanchana Chansung, Kitsada Wudhikarn, Arnuparp Lekhakula, Udomsak Bunworasate, Archrob Khuhapinant, Jakrawadee Julamanee, Nisa Makruasri, Lalita Norasetthada, Pimjai Niparuck, Kannadit Prayongratana, Supachai Ekwattanakit, Somchai Wongkhantee, Tontanai Numbenjapon, Weerasak Nawarawong, Tawatchai Suwanban, Suporn Chuncharunee, Chittima Sirijerachai, Peerapon Wong, Pannee Praditsuktavorn, Nonglak Kanitsap |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Kaplan-Meier Estimate Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine T-cell lymphoma Humans Public Health Surveillance B-cell lymphoma Prospective cohort study Performance status business.industry Event free survival Lymphoma T-Cell Peripheral Hematology General Medicine Middle Aged medicine.disease Prognosis Thailand Peripheral T-cell lymphoma Progression-Free Survival Standardized mortality ratio Treatment Outcome 030220 oncology & carcinogenesis Cohort Female business 030215 immunology |
| Zdroj: | Hematological oncologyREFERENCES. 37(5) |
| ISSN: | 1099-1069 |
| Popis: | Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2-year EFS and 2-year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2-y OS 92% vs 18.8%; HR, 0.1; P < .001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6-22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text